Johnson & Johnson (JNJ) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-28..
Operating margin
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | (m) | Operating Income (Loss) |
| Revenue | 97.93B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 31.43B USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 25.14B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-28 | (m) | $97.93B | $31.43B | (m) | $25.14B | (m) |
| 2026-03-29 | (m) | $96.36B | $31.00B | (m) | $24.60B | (m) |
| 2025-12-28 | (m) | $94.19B | $30.26B | $109.00M | $23.68B | (m) |
| 2025-09-28 | (m) | $92.15B | $29.42B | (m) | $23.38B | (m) |
| 2025-06-29 | (m) | $90.63B | $29.08B | (m) | $22.93B | (m) |
| 2025-03-30 | (m) | $89.33B | $28.32B | (m) | $22.72B | (m) |
| 2024-12-29 | (m) | $88.82B | $27.47B | $1.84B | $22.87B | (m) |
| 2024-09-29 | (m) | $87.70B | $27.14B | (m) | $22.23B | (m) |
| 2024-06-30 | (m) | $86.58B | $26.78B | (m) | $22.15B | (m) |
| 2024-03-31 | (m) | $85.65B | $26.38B | (m) | $21.86B | (m) |
| 2023-12-31 | (m) | $85.16B | $26.55B | $483.00M | $21.51B | (m) |
| 2023-10-01 | (m) | $98.66B | $32.33B | (m) | $25.56B | (m) |
| 2023-07-02 | (m) | $97.77B | $32.18B | (m) | $25.40B | (m) |
| 2023-04-02 | (m) | $96.26B | $31.89B | (m) | $24.96B | (m) |
| 2023-01-01 | (m) | $94.94B | $31.09B | (m) | $24.77B | (m) |
| 2022-10-02 | (m) | $96.04B | $31.28B | (m) | $25.41B | (m) |
| 2022-07-03 | (m) | $95.59B | $30.72B | (m) | $25.32B | (m) |
| 2022-04-03 | (m) | $94.88B | $30.39B | (m) | $25.16B | (m) |
| 2022-01-02 | (m) | $93.78B | $29.86B | (m) | $24.66B | (m) |
| 2021-10-03 | (m) | $91.45B | $29.71B | (m) | $23.96B | (m) |
| 2021-07-04 | (m) | $89.19B | $29.44B | (m) | $23.39B | (m) |
| 2021-04-04 | (m) | $84.21B | $28.43B | (m) | $22.31B | (m) |
| 2021-01-03 | (m) | $82.58B | $28.43B | (m) | $22.08B | (m) |
| 2020-09-27 | (m) | $80.86B | $27.75B | (m) | $21.67B | (m) |
| 2020-06-28 | (m) | $80.50B | $27.64B | (m) | $21.61B | (m) |
| 2020-03-29 | (m) | $82.73B | $28.00B | (m) | $22.16B | (m) |
| 2019-12-29 | (m) | $82.06B | $27.56B | (m) | $22.18B | (m) |
| 2019-09-29 | (m) | $81.71B | (m) | (m) | $22.13B | (m) |
| 2019-06-30 | (m) | $81.33B | (m) | (m) | $22.30B | (m) |
| 2019-03-31 | (m) | $81.59B | (m) | (m) | $22.50B | (m) |
| 2018-12-30 | (m) | $81.58B | (m) | (m) | $22.54B | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | $22.49B | (m) |
| 2018-07-01 | (m) | $80.68B | (m) | (m) | $22.47B | (m) |
| 2018-04-01 | (m) | $78.69B | (m) | (m) | $22.02B | (m) |
| 2017-12-31 | (m) | $76.45B | (m) | (m) | $21.52B | (m) |
| 2017-10-01 | (m) | (m) | (m) | (m) | $20.78B | (m) |
| 2017-07-02 | (m) | (m) | (m) | (m) | $20.25B | (m) |
| 2017-04-02 | (m) | (m) | (m) | (m) | $20.14B | (m) |
| 2017-01-01 | (m) | $71.89B | (m) | (m) | $20.07B | (m) |
| 2015-03-29 | $21.77B | (m) | (m) | (m) | $21.62B | (m) |
| 2014-12-28 | $21.59B | (m) | (m) | (m) | $21.95B | (m) |
| 2014-09-28 | $21.62B | (m) | (m) | (m) | $22.05B | (m) |
| 2014-06-29 | $18.43B | (m) | (m) | (m) | $21.89B | (m) |
| 2014-03-30 | $17.58B | (m) | (m) | (m) | $21.79B | (m) |
| 2013-12-29 | $16.41B | (m) | (m) | (m) | $21.83B | (m) |
| 2013-09-29 | $16.72B | (m) | (m) | (m) | $21.57B | (m) |
| 2013-06-30 | $16.67B | (m) | (m) | (m) | $21.49B | (m) |
| 2013-03-31 | $14.31B | (m) | (m) | (m) | $21.08B | (m) |
| 2012-12-30 | $14.96B | (m) | (m) | (m) | $20.87B | (m) |
| 2012-09-30 | $12.46B | (m) | (m) | (m) | $20.67B | (m) |
| 2012-07-01 | $13.29B | (m) | (m) | (m) | $20.68B | (m) |
| 2012-04-01 | $14.17B | (m) | (m) | (m) | $20.93B | (m) |
| 2012-01-01 | $13.77B | (m) | (m) | (m) | $20.97B | (m) |
| 2011-10-02 | (m) | (m) | (m) | (m) | $20.69B | (m) |
| 2011-07-03 | (m) | (m) | (m) | (m) | $20.16B | (m) |
| 2011-04-03 | (m) | (m) | (m) | (m) | $19.70B | (m) |
| 2011-01-02 | $17.70B | (m) | (m) | (m) | $19.42B | (m) |
| 2010-10-03 | (m) | (m) | (m) | (m) | $19.87B | (m) |
| 2010-07-04 | (m) | (m) | (m) | (m) | $19.93B | (m) |
| 2010-01-03 | $16.58B | (m) | (m) | (m) | $19.80B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |